Current and future chemical therapies for treating anaemia in chronic kidney disease

References

• Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631–1634.
   PubMed Web of Science ®Google Scholar
• Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37:395–402.
   PubMedGoogle Scholar
• Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:153–159.
   PubMed Web of Science ®Google Scholar
• Handelman GJ, Levin NW. Red cell survival: relevance and mechanism involved. J Ren Nutr. 2010;20(5 Suppl):S84–S88.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Pissas G, Antoniadi G, et al. Kynurenine, by activating aryl hydrocarbon receptor, decreases erythropoietin and increases hepcidin production in HepG2 cells: a new mechanism for anemia of inflammation. Exp Hematol. 2016;44(1):60–67.
   PubMed Web of Science ®Google Scholar
• Asai H, Hirata J, Hirano A, et al. Activation of aryl hydrocarbon receptor mediates suppression of hypoxia-inducible factor-dependent erythropoietin expression by indoxyl sulfate. Am J Physiol Cell Physiol. 2016;310(2):C142–C150.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098.
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Uno H, Lewis EF, et al.; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–1155.
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in united states dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10:1814–1821.
   PubMed Web of Science ®Google Scholar
• Evans M, Suttorp MM, Bellocco R, et al. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant. 2016;31:628–635.
   PubMed Web of Science ®Google Scholar
• Fuller DS, Zepel L, Bieber BA, et al. Hemodialysis facility variation in hospitalization and transfusions using medicare claims: the DOPPS practice monitor for US dialysis care. Am J Kidney Dis. 2016;67:337–340.
   PubMed Web of Science ®Google Scholar
• Fuller DS, Bieber BA, Pisoni RL, et al. International comparisons to assess effects of payment and regulatory changes in the united states on anemia practice in patients on hemodialysis: the dialysis outcomes and practice patterns study. J Am Soc Nephrol. 2016;27:2205–2215.
   PubMed Web of Science ®Google Scholar
• Kang DH, Yoon KI, Han DS. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2877–2883.
   PubMed Web of Science ®Google Scholar
• Barhoumi T, Briet M, Kasal DA, et al. Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens. 2014;32:784–794.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Canaud B, et al.; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25:2846–2850.
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:299.
   Web of Science ®Google Scholar
• Mohan N, Monickaraj F, Balasubramanyam M, et al. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications. 2012;26:435–441.
   PubMed Web of Science ®Google Scholar
• Hernández C, Fonollosa A, García-Ramírez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028–2033.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Cancarini A, Morescalchi F, et al. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. Diabetes Metab. 2014;40:445–451.
   PubMed Web of Science ®Google Scholar
• Hu L-M, Lei X, Ma B, et al. Erythropoietin receptor positive circulating progenitor cells and endothelial progenitor cells in patients with different stages of diabetic retinopathy. Chin Med Sci J. 2011;26:69–76.
   PubMedGoogle Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–792.
   PubMed Web of Science ®Google Scholar
• Garcia-Ramírez M, Hernández C, Ruiz-Meana M, et al. Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: essential role of JAK2/PI3K signaling. Cell Signal. 2011;23:1596–1602.
   PubMed Web of Science ®Google Scholar
• Xu G, Kang D, Zhang C, et al. Erythropoietin protects retinal cells in diabetic rats through upregulating ZnT8 via activating ERK pathway and inhibiting HIF-1α expression. Invest Ophthalmol Vis Sci. 2015;56:8166–8178.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi J, Morikawa S, Shimizu K, et al. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res. 2013;106:64–73.
   PubMed Web of Science ®Google Scholar
• Minutolo R, Borzumati M, Sposini S, et al. Dosing penalty of erythropoiesis-stimulating agents after switching from originator to biosimilar preparations in stable hemodialysis patients. Am J Kidney Dis. 2016;68:170–172.
   PubMed Web of Science ®Google Scholar
• Affymax and Takeda announce a nationwide voluntary recall of all lots of OMONTYS (peginesatide) injection. Available from: http://www.takeda.com/news/2013/20130224_5664.html
   Google Scholar
• Verhoef JJ, Carpenter JF, Anchordoquy TJ, et al. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today. 2014;19:1945–1952.
   PubMed Web of Science ®Google Scholar
• Weaver JL, Boyne M, Pang E, et al. Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog. Toxicol Appl Pharmacol. 2015;287:246–252.
   PubMed Web of Science ®Google Scholar
• Rabinowitz MH. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J Med Chem. 2013;56:9369–9402.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016;11:982–991.
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in non dialysis dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30:1665–1673.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912–924.
   PubMed Web of Science ®Google Scholar
• Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27:1225–1233.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Spinowitz BS, Hartman CS, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Martin ER, Smith MT, Maroni BJ, et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380–388.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier NCT02260193. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02260193&Search=Search
   Google Scholar
• Macdougall I, Akizawa T, Berns J, et al. Molidustat increases haemoglobin in erythropoiesis stimulating agents (esa)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND). In: 53rd Congress ERA-EDTA; 2016 May 21–24; Vienna. p. abstract So036.
   Google Scholar
• Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. Plos One. 2014;9:e111838.58.
   Web of Science ®Google Scholar
• Brigandi RA, Johnson B, Oei C, et al.; PHI112844 Investigators. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;67:861–871.
   PubMed Web of Science ®Google Scholar
• Safety, tolerability, PK and PD study of JTZ-951 in anemic subjects with end-stage renal disease. U.S. National Institutes of Health, 2013. Available from: https://clinicaltrials.gov/ct2/show?term5jtz-951&rank52
   Google Scholar
• Pilot PK/PD study of DS-1093a in patients with chronic kidney disease. U.S. National Institutes of Health, 2014. Available from: https://clinicaltrials.gov/ct2/show?term5ds1093a&rank51
   Google Scholar
• Murata M, Eto Y, Shibai H, et al. Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain. Proc Natl Acad Sci U S A. 1988;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res. 2003;282:110–120.
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41:155.e17–166.e17.
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24:744–752.
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov K, Salogub G, Khuazheva N, et al. ACE-011, a soluble activin receptor type IIa IgG-FC fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis. Blood. 2009;114(22). (ASH AnnualMeeting Abstracts):Abstract749.
   Web of Science ®Google Scholar
• ClinicalTrials.gov identifier NCT01146574. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01146574&Search=Search
   Google Scholar
• Malluche H, Hurska K, Singh HN, et al. Sotatercept: initial signal-seeking quantitative computed tomography results for bone mass and vascular calcification in hemodialysis patients treated with escalating doses: interim analysis of ACE-011-REN-001 [ASN abstract TH-PO602]. J Am Soc Nephrol. 2014;25:245A.
   Google Scholar
• Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016;24(4):1517–1525.
   PubMed Web of Science ®Google Scholar
• Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89:766–770.
   PubMed Web of Science ®Google Scholar
• Neil G Prolonged secretion of physiological levels of autologous EPO by TARGT. In: Presented at: XXII annual congress of the european society of gene and cell therapy; 2014 Oct 23–26; The Hague, The Netherlands.
   Google Scholar
• Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25:2722–2730.
   PubMed Web of Science ®Google Scholar
• Grimmelt A-C, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol. 2009;71:125–129.
   PubMed Web of Science ®Google Scholar
• Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29:833–842.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patietns with CKD. Clin J Am Soc Nephrol. 2014;9:705–712.
   PubMed Web of Science ®Google Scholar
• Wikstrom B, Bhandari S, Barany P et al. Monofer, a novel intravenous iron oligosaccharide for treatment of iron deficiency in patients with chronic kidney disease (CKD). In: Poster No.M560 world congress of nephrology; 2009 May 22–26; Milan, Italy.
   Google Scholar
• Visciano B, Nazzaro P, Tarantino G, et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease. G Ital Nefrol. 2013;30:5.
   Google Scholar
• Pisani A, Riccio E, Sabbatini M, et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015;30:645–652.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36:478–487.
   PubMed Web of Science ®Google Scholar
• Lewis J, Sika M, Koury M, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26:493–503.
   PubMed Web of Science ®Google Scholar
• Umanath K, Jalal DI, Greco BA, et al.; Collaborative Study Group. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26:2578–2587.
   PubMed Web of Science ®Google Scholar
• Block G, Fishbane S, Rodriguez M, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3–5. Am J Kidney Dis. 2014;65:728–736.
   PubMed Web of Science ®Google Scholar
• Phan O, Maillard M, Peregaux C, et al. PA21, a new iron-based non calcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013;346:281–289.
   PubMed Web of Science ®Google Scholar
• Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013;37:346–358.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lin V, Guss C, et al. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 2015;88:1187–1194.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 2007;30:15–30.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014;124:2569–2574.
   PubMed Web of Science ®Google Scholar
• Van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014;124:2643–2646.
   PubMed Web of Science ®Google Scholar
• [ cited 2016 May 29]. Available from: http://www.pieris.com/news-and-events/press-releases/detail/524/accessed
   Google Scholar
• Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21:2151–2156.
   PubMed Web of Science ®Google Scholar